In process assessment of critical process parameters impacting CAR T-cell potency, metabolic fitness and phenotype
Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a promising therapeutic approach for several cancers. Despite the growing interest, the widespread use of CAR T-cell therapies has been restricted due to their high cost and the challenges that arise when compared with traditional methods for manufacturing and product QC. Developing sensitive and reliable analytics to characterize CAR-T products' critical quality attributes (CQAs) and tailoring the cell expansion process to achieve these CQAs provides tools for a more consistent manufacturing process.
Join Dr. Laurissa Ouaguia, Scientist, Reagents and Application Development, Agilent Technologies, as she discusses Agilent’s portfolio of cell analysis tools. She will also demonstrate how they can be applied during the production of CAR T-cells using the functionally closed and automated Lonza Cocoon® Platform for cell manufacturing. This approach provides a deeper understanding of the immune phenotype, metabolic fitness, and cytotoxic function of the CAR T-cells throughout the production, allowing for more informed process development.
Key learning objectives
- Explore the Agilent Seahorse XF Analyzer for real-time live-cell metabolic assay and the impedance-based xCELLigence RTCA eSight system for real-time immune cell killing potency assay.
- Understand how Agilent cell analysis platforms deliver reliable, reproducible, and sensitive analytics, providing a deeper understanding of CAR T-cells' immune phenotype, metabolic fitness, and cytotoxic function throughout the production in an automated cell manufacturing platform
- Discover how enhanced analytics can provide valuable tools for in-process analysis during CAR T-cell manufacturing, potentially shortening production timelines and reducing associated costs
Who should attend?
- Researchers and scientists specializing in cell therapy
- Experts in cell therapy analytics and process development
- Cell therapy manufacturing specialists
- Quality control (QC) professionals in the cell therapy field
- Professionals in the pharmaceutical and biopharmaceutical industries focusing on cell therapy
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
Dr. Laurissa Ouaguia is a scientist with expertise in immunology, viral infections, and cancer. She holds Masters degrees in animal physiology and biochemistry and a PhD in immunology. Her research has been focused on multicolor flow cytometry and multiplexing cytokines assays in HBV and HCV contexts. In her role as R&D scientist at Agilent, she strives to better understand cellular phenotype, metabolism and function using Agilent cutting edge analytical tools (xCELLigence RTCA, Seahorse and NovoCyte flow cytometers).